What Researchers Did
Researchers reviewed medical records of patients who developed botulism from cosmetic injections at a single center over a 10-year period to understand the outbreak, patient characteristics, and treatment outcomes.
What They Found
Over a decade, 161 cases of cosmetic iatrogenic botulism were identified, with 49.69% of patients requiring hospitalization. Most patients received botulinum toxin from unlicensed practitioners in nonmedical settings, and 60% of cases were classified as severe or moderate. Symptoms resolved within a mean of 24.85 days, and treatments included antitoxin administration, hyperbaric oxygen therapy, and supportive care.
What This Means for Canadian Patients
Canadian patients considering cosmetic injections should ensure they receive treatment from licensed medical professionals using approved products to avoid serious health risks. This study highlights the potential for severe outcomes, including hospitalization and prolonged recovery, from unregulated procedures and counterfeit botulinum toxin. If symptoms like muscle weakness or difficulty swallowing appear after a cosmetic injection, immediate medical attention is crucial.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This study is a retrospective case series from a single center, which means its findings may not apply to all populations or settings.